Please login to the form below

alpharadin

This page shows the latest alpharadin news and features for those working in and with pharma, biotech and healthcare.

FDA clears Bayer/ Algeta's prostate cancer radiotherapy

Analysts have predicted that Xofigo (formerly known as Alpharadin) could achieve sales of $650m within three years of launch and more than $1bn a year at its peak if follow-up

Latest news

Bayer pins hopes on five potential blockbusters

Riociguat, alpharadin, Stivarga, Eylea, and Xarelto expected to reach sales of 5.5bn by 2015. ... The German company's expectations are high for it yet to be approved riociguat and alpharadin (radium-223 chloride), as well as the recently launched
FDA fast-tracks Bayer's prostate cancer radiotherapy

Priority review for radium-223 dichloride, formerly called Alpharadin. Bayer said yesterday the US FDA had granted fast-track status to its radiotherapeutic drug for castration-resistant prostate cancer (CRPC), raising ... The FDA granted priority review
Bayer points to four blockbusters in portfolio

Alpharadin is in phase III testing for bone metastases in patients with castration-resistant prostate cancer and should be filed for approval in the US and Europe in mid-2012.
Bayer's prostate cancer drug fast-tracked

Bayer Healthcare has said its investigational prostate cancer treatment Alpharadin has been fast-tracked for approval by the US Food and Drug Administration (FDA). ... Bayer holds the global rights to develop and commercialise Alpharadin. However, in the

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest appointments

Bayer’s former oncology head Robert Rosen joins AP Pharma

Rosen also led premarket activities for Stivarga (regorafenib) in its indications for gastrointestinal stromal tumours and colon cancer, as well as for alpharadin in prostate cancer.
Former Bayer oncology head Robert Rosen joins AP Pharma's board

He was also involved in pre-market activities for regorafenib in the treatment of patients with gastrointestinal stromal tumours and colon cancer, as well as alpharadin for prostate cancer.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Account Management: Competitive Salary Offered

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

PMHub

Add my company

Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...